Sysmex XR-Series Aims to Redefine Hematology Lab Workflow

CHICAGO, IL – May 28, 2026 – Sysmex America today announced the launch of its next-generation XR-Series™ hematology solution, a move poised to significantly impact clinical laboratories grappling with increasing sample volumes and the unceasing demand for faster, more accurate diagnostic results. Building on the legacy of its widely adopted XN-Series™, the new platform is engineered to enhance throughput and analytical depth while streamlining the complex daily operations of modern medical labs.

The introduction comes at a critical time for the healthcare industry, where laboratory efficiency is directly tied to patient outcomes and operational costs. The XR-Series is designed to be the new workhorse for these environments, promising not just an evolution of existing technology but a thoughtful redesign of the entire hematology workflow.

A New Era of Diagnostic Efficiency

At the heart of the new system is the XR-10 Automated Hematology Module, a unit built for the high-stakes environment of high-complexity laboratories where speed and consistency are paramount. The XR-Series expands on the trusted capabilities of its predecessor by integrating higher throughput, more sophisticated analytics, and a suite of complementary solutions designed to automate and simplify daily lab tasks.

"The XR-Series reflects our commitment to helping laboratories work smarter without disrupting the workflows they depend on," said Dan Zortman, CEO of Sysmex America, in a statement. "By combining proven reliability, advanced analytics and the support of our award-winning service teams, the XR-Series analyzers help laboratories deliver the accuracy and precision clinicians rely on for outstanding patient care."

This launch places Sysmex in a competitive field alongside other industry giants like Siemens Healthineers, Abbott, and Beckman Coulter, all of whom are vying to equip high-volume labs with solutions that minimize manual intervention and maximize output. However, Sysmex is betting that its focus on advanced analytical intelligence and a smooth upgrade path will be a key differentiator. The modular design of the XR-Series, including the high-volume XR-9000™ configuration, allows for scalable automation, integrating with modules for everything from smear preparation to sample sorting and archiving, offering a tailored solution rather than a one-size-fits-all box.

Beyond the Count: Advanced Analytics for Deeper Insights

While increased speed is a major selling point, the true innovation of the XR-Series lies in its enhanced analytical capabilities, which promise to deliver deeper clinical insights and bolster diagnostic confidence. The system moves beyond simple cell counts to provide a more detailed picture of a patient's hematological status.

A key advancement is a new formulation for the WBC differential reagent, which, when combined with innovative 3D scattergram visualization, provides unprecedented clarity in cell population analysis. These rotatable 3D scattergrams allow technicians to inspect morphological abnormalities from multiple angles, improving the separation of cell clusters, especially in challenging samples with low white blood cell counts. This visual depth helps improve flagging accuracy for abnormal cells, reducing the rate of false positives that trigger time-consuming manual slide reviews.

Perhaps the most significant differentiator is the optional WPC (White Precursor and Pathological Cell) channel. This specialized channel refines the system's flagging capabilities by helping to separate suspect malignant cells from reactive atypical cells. For laboratories, this means a more intelligent sorting of samples, potentially classifying them as 'reactive,' 'suspected malignant,' or 'negative' with greater certainty. The clinical and economic impact is substantial; by reducing the number of manual slide reviews, labs can save significant labor costs and accelerate the delivery of critical results to clinicians. Furthermore, the WPC channel unlocks the ability to measure hematopoietic progenitor cells (HPC), offering a rapid and reliable method for monitoring stem cell mobilization that correlates closely with traditional flow cytometry.

A Seamless Evolution with Tangible Economic Benefits

For the thousands of laboratories currently relying on Sysmex's XN-Series, the transition to the XR-Series is designed to be a seamless evolution rather than a disruptive overhaul. The company has deliberately maintained the familiar user interface and operational logic of the previous generation, ensuring that lab staff can quickly adapt to the new system with minimal retraining. This approach respects the investment labs have already made in training and workflow development, making the upgrade a more attractive proposition.

The economic argument for adoption extends beyond ease of use. While the initial investment for high-throughput analyzers can be substantial, ranging from $50,000 to over $120,000, the XR-Series is positioned to deliver a strong return on investment through operational efficiencies. The system's intelligent reflex functionality automatically re-runs or performs extended analysis on samples that meet certain criteria, increasing walk-away time for technicians and ensuring comprehensive results without manual intervention.

By dramatically improving first-pass accuracy and reducing the need for manual interventions, the platform directly addresses major cost centers in the lab. The reduction in manual blood film reviews alone represents a significant saving in both labor and materials. This focus on workflow optimization and cost-containment makes the XR-Series a compelling option not just for clinical scientists, but for the healthcare administrators and procurement officers who manage laboratory budgets.

A Proven Platform on a Global Stage

While the XR-Series is just now making its official debut in the United States, it is not an unproven technology. The platform received U.S. Food and Drug Administration (FDA) 510(k) clearance in mid-2025, following successful launches and widespread adoption in Japan and across Europe, where it has been available since July 2023. This established global track record provides an extra layer of confidence for U.S. laboratories considering the new system.

This phased global rollout demonstrates a platform that has been refined through real-world use in diverse clinical settings. Backed by Sysmex America's award-winning service and support teams, laboratories adopting the XR-Series can expect a high level of reliability and expert assistance to ensure their systems maintain peak performance. As clinical laboratories continue to navigate the pressures of a demanding healthcare landscape, the introduction of the XR-Series represents a significant step forward in the quest for faster, more intelligent, and more efficient diagnostic hematology.